The proteasome inhibitor PS-341 modulates VEGF secretion and activity in multiple myeloma.

被引：0
|
作者：
Mitsiades, N
Mitsiades, CS
Poulaki, V
Fanourakis, G
Chauhan, D
Munshi, NC
Hideshima, T
Anderson, KC
机构：
[1] Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA
[2] Harvard Univ, Massachusetts Eye & Ear Infirm, Sch Med, Boston, MA USA
来源：
BLOOD | 2002年 / 100卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
3220
引用
收藏
页码：815A / 815A
页数：1
相关论文
共 50 条
  • [31] PS-341: prospecting a new hope for myeloma
    Berenson, JR
    BLOOD, 2003, 101 (04) : 1210 - 1210
  • [32] Proteasome inhibitor PS-341 attenuates flow-induced pulmonary arterial hypertension
    Wang, Ya-Yun
    Luan, Yun
    Zhang, Xue
    Lin, Mei
    Zhang, Zhao-Hua
    Zhu, Xiao-Bo
    Ma, Yu
    Wang, Yi-Biao
    CLINICAL AND EXPERIMENTAL MEDICINE, 2014, 14 (03) : 321 - 329
  • [33] Proteasome inhibitor PS-341 attenuates flow-induced pulmonary arterial hypertension
    Ya-Yun Wang
    Yun Luan
    Xue Zhang
    Mei Lin
    Zhao-Hua Zhang
    Xiao-Bo Zhu
    Yu Ma
    Yi-Biao Wang
    Clinical and Experimental Medicine, 2014, 14 : 321 - 329
  • [34] Blockade of ubiquitin-conjugating enzyme CDC34 enhances anti-myeloma activity of Bortezomib/Proteasome inhibitor PS-341
    Dharminder Chauhan
    Guilan Li
    Teru Hideshima
    Klaus Podar
    Reshma Shringarpure
    Constantine Mitsiades
    Nikhil Munshi
    P Renee Yew
    Kenneth C Anderson
    Oncogene, 2004, 23 : 3597 - 3602
  • [35] Blockade of ubiquitin-conjugating enzyme CDC34 enhances anti-myeloma activity of Bortezomib/Proteasome inhibitor PS-341
    Chauhan, D
    Li, GL
    Hideshima, T
    Podar, K
    Shringarpure, R
    Mitsiades, C
    Munshi, N
    Yew, PR
    Anderson, KC
    ONCOGENE, 2004, 23 (20) : 3597 - 3602
  • [36] The proteasome inhibitor PS-341 sensitizes tumor cells to TRAIL-mediated lysis
    Sayers, TJ
    Brooks, AD
    Seki, N
    Raziuddin, A
    Ma, WH
    Blazar, B
    Elliott, PJ
    Murphy, WJ
    FASEB JOURNAL, 2002, 16 (04): : A669 - A669
  • [37] The proteasome inhibitor bortezomib (PS-341) is active against Waldenstrom's macroglobulinemia (WM).
    Mitsiades, CS
    Mitsiades, N
    McMullan, CJ
    Poulaki, V
    Shringarpure, R
    Hideshima, T
    Chauhan, D
    Treon, SP
    Richardson, PG
    Munshi, NC
    Joseph, M
    Libermann, TA
    Anderson, KC
    BLOOD, 2003, 102 (11) : 181A - 181A
  • [38] Reduced dose PAD combination therapy (PS-341/bortezomib, adriamycin and dexamethasone) for previously untreated patients with multiple myeloma.
    Popat, R
    Oakervee, HE
    Curry, N
    Foot, N
    Morris, C
    Drake, M
    Agrawal, S
    Smith, P
    Schenkein, D
    Esseltine, DL
    Cavenagh, JD
    BLOOD, 2005, 106 (11) : 717A - 718A
  • [39] Anti-tumor activity of the proteasome inhibitor PS-341 in mantle cell lymphoma B cells.
    Pham, L
    Tamayo, A
    Lo, P
    Yoshimura, L
    Ford, RJ
    BLOOD, 2001, 98 (11) : 465A - 465A
  • [40] Gene expression profiling in the prediction of response of multiple myeloma to the proteasome inhibitor PS-341.
    Shaughnessy, J
    Zhan, FH
    McCastlain, K
    Tian, EM
    Tricot, G
    BLOOD, 2002, 100 (11) : 390A - 390A
12345